OSE Immunotherapeutics and Boehringer Ingelheim expand partnership, adding two projects to their anti-SIRPa immuno-oncology programs, with Boehringer Ingelheim paying €13.
OSE Immunotherapeutics and Boehringer Ingelheim expand partnership, adding two projects to their anti-SIRPa immuno-oncology programs. The projects aim to reach more patients and acquire a new asset, alongside Phase I clinical studies of BI 765063 and BI 770371 in advanced solid tumors. Boehringer Ingelheim pays €13.5m upfront and €17.5m near-term milestone for a preclinical anti-PD1/cytokine asset, and €25.3m royalty buy-out for the anti-SIRPa programs.
May 22, 2024
3 Articles